CD4 and neoplasm: In blood, before PD-1 blockade, tumor-TCR-matched CD4+ cells were predominantly GZMB+ in pre-atezolizumab blood (average 35%–37% of branches A and B), with a minority of GZMK+ (2.8%–5.2% of branches A and B).